Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor...
Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients
About this item
Full title
Author / Creator
Publisher
Bridgewater, NJ: Elsevier
Journal title
Language
English
Formats
Publication information
Publisher
Bridgewater, NJ: Elsevier
Subjects
More information
Scope and Contents
Contents
AbstractBackgroundThe dipeptidyl-peptidase-4 (DPP-4) inhibitor linagliptin is under clinical development for treatment of type 2 diabetes mellitus (T2DM). In previous studies in white populations it showed potential as a once-daily oral antidiabetic drug. ObjectivesIn compliance with regulatory requirements for new drugs intended for use in the Jap...
Alternative Titles
Full title
Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_878029955
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_878029955
Other Identifiers
ISSN
0149-2918
E-ISSN
1879-114X
DOI
10.1016/j.clinthera.2011.06.005
